AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antipsychotic Abilify (aripiprazole) approved for marketing in Europe.
2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced that the European Commission has granted marketing authorization for Abilify (aripiprazole), an antipsychotic medication, for the treatment of schizophrenia.
"Receiving marketing approval for Abilify in 25 nations of the European Union marks a significant milestone for Abilify and for both companies, bringing an important medicine one step closer to the millions of people in Europe living with schizophrenia," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb.
"For patients with schizophrenia, Abilify has a unique pharmacology among the atypical antipsychotics and has demonstrated proven efficacy with a comprehensive tolerability and safety profile," said Tatsuo Higuchi, president & representative director, Otsuka Pharmaceutical Co., Ltd.
"We are proud to have discovered Abilify and now be able to offer this important therapy in the European Union for people in need of treatment options of schizophrenia. It will also give Otsuka an opportunity to strengthen the foundations to introduce more of Otsuka's innovative medicines to people in Europe," Higuchi said.
Otsuka Pharmaceutical Europe, Ltd., the London subsidiary of Otsuka Pharmaceutical Co., Ltd., holds the marketing authorization for Abilify in Europe. Bristol-Myers Squibb and Otsuka will co-promote Abilify in several European countries.
- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce...
- Press release article from: PR Newswire February 7, 2006 700+ words
...Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced...newly available options of ABILIFY(R) (aripiprazole...solution (1 mg/mL). The ABILIFY 2 mg tablet equips physicians...difficulty swallowing tablets. ABILIFY is indicated for the treatment...
- Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly...
- Press release article from: PR Newswire August 17, 2006 700+ words
Provides Another ABILIFY Formulation Option for...Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) DISCMELT(TM...antipsychotic medication ABILIFY(R) (aripiprazole...
- Strong results for B-MS/Otsuka's Abilify.(Bristol-Myers Squibb Co.)(Otsuka...
- Newspaper article from: Pharma Marketletter March 20, 2006 700+ words
...Squibb and Japan's Otsuka Pharmaceutical says that their co-devloped antipsychotic, Abilify (aripiprazole) demonstrated...schizophrenia treated with Abilify experienced significantly...more patients in the Abilify group than the SOC arm...
- Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the...
- Press release article from: PR Newswire June 16, 2003 700+ words
...pharmaceutical and health care issues, forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market...at Decision Resources. "The launch of Abilify, novel formulations of atypical antipsychotics...
- FDA clears new indication for Abilify.(Otsuka Pharmaceutical Company Ltd. and...
- Newspaper article from: Pharma Marketletter March 21, 2005 700+ words
Tokyo, Japan-based Otsuka Pharmaceutical and the USA's Bristol-Myers...new use for their antipsychotic Abilify (ariprazole). The agent is now...relapses, of bipolar-1 disorder. Abilify, which analysts have forecast...
- B-M S and Otsuka launch Abilify Discmelt.(Bristol-Myers Squibb and Otsuka...
- Newspaper article from: Pharma Marketletter September 4, 2006 700+ words
...drugmaker Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have announced the launch of an orally disintegrating...version of their co-developed antipsychotic Abilify (arpiprazol), known as Abilify Discmelt. This follows the US Food and...
- Abilify wins clearance.(RX: RETAIL PHARMACY: Branded Drugs)(FDA approves...
- Magazine article from: Chain Drug Review March 17, 2008 700+ words
The FDA has approved Abilify for the treatment of acute bipolar I disorder in patients between ages 10 and 17. The product is marketed by Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Co.
- B-MS and Otsuka's Abilify oral solution approved by FDA.(Bristol-Myers Squibb...
- Newspaper article from: Pharma Marketletter January 3, 2005 700+ words
...Myers Squibb and Japanese drugmaker Otsuka Pharmaceutical say they have received US Food and Drug...approval for an oral formulation of Abilify (aripiprazole), which is indicated...Marketletters passim). The oral solution of Abilify, which was first launched in 2002 for...